Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in
Sonia Pernas1, Anna Petit2, Fina Climent2
1Department of Medical Oncology-Breast Cancer Unit, Institut Català d'Oncologia (ICO)-H.U.Bellvitge-Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain.
Frontiers in Oncology
|October 11, 2019
Abstract:
[This corrects the article DOI: 10.3389/fonc.2019.00707.].
Keywords:
HER2breast cancergene expressionmolecular intrinsic subtypepaired samplespathological complete responseresidual diseaseMore Related Videos
06:06High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts
Published on: December 20, 2024
1.1K
11:34Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
13.0K
